Inventiva Pharma   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Daix France (2011)

Organization Overview

First Clinical Trial
2015
NCT02503644
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Inventiva Pharma

Active Ingredients

Drugs in Phase 3 Trials (1)

lanifibranor (6 trials)

Drugs in Phase 2 Trials (2)

empagliflozin (jardiance) (1 trial)

odiparcil (1 trial)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Fatty Liver (Phase 2)

Liver Diseases (Phase 2)

Mucopolysaccharidoses (Phase 2)

Mucopolysaccharidosis VI (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Scleroderma, Diffuse (Phase 2)

Scleroderma, Systemic (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 4